Tanaka H - Search Results

1

A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.

Tamiya M, Tamiya A, Kaneda H, Nakagawa K, Yoh K, Goto K, Okamoto H, Shimokawa T, Abe T, Tanaka H, Daga H, Takeda K, Hirashima T, Atagi S. Tamiya M, et al. Among authors: tanaka h. Med Oncol. 2016 Jan;33(1):2. doi: 10.1007/s12032-015-0715-7. Epub 2015 Nov 24. Med Oncol. 2016. PMID: 26603297 Clinical Trial.

2

[A case of squamous cell carcinoma of unknown primary site with involvement of cervico-mediastinal lymph nodes successfully treated by chemoradiotherapy].

Watanabe S, Tanaka J, Tsuboi K, Tanaka H, Kagamu H, Yoshizawa H, Suzuki E, Gejyo F. Watanabe S, et al. Among authors: tanaka j, tanaka h. Gan To Kagaku Ryoho. 2006 Oct;33(10):1493-5. Gan To Kagaku Ryoho. 2006. PMID: 17033245 Japanese.

3

[Combination of cisplatin and vinorelbine as adjuvant chemotherapy in non-small cell lung cancer patients--feasibility assessment of 5 consecutively treated patients].

Hirahara K, Tanaka J, Itoh R, Kuriyama H, Tanaka H, Kagamu H, Yoshizawa H, Gejyo F. Hirahara K, et al. Among authors: tanaka j, tanaka h. Gan To Kagaku Ryoho. 2008 Jan;35(1):109-11. Gan To Kagaku Ryoho. 2008. PMID: 18195537 Clinical Trial. Japanese.

4

Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer.

Hayashi Y, Kuriyama H, Umezu H, Tanaka J, Yoshimasu T, Furukawa T, Tanaka H, Kagamu H, Gejyo F, Yoshizawa H. Hayashi Y, et al. Among authors: tanaka j, tanaka h. Intern Med. 2009;48(4):203-8. doi: 10.2169/internalmedicine.48.1659. Epub 2009 Feb 16. Intern Med. 2009. PMID: 19218769 Free article.

5

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.

Watanabe S, Tanaka J, Ota T, Kondo R, Tanaka H, Kagamu H, Ichikawa K, Koshio J, Baba J, Miyabayashi T, Narita I, Yoshizawa H. Watanabe S, et al. Among authors: tanaka j, tanaka h. BMC Cancer. 2011 Jan 1;11:1. doi: 10.1186/1471-2407-11-1. BMC Cancer. 2011. PMID: 21194487 Free PMC article.

6

[Associations between Clinical Factors and Acute Renal Failure Due to Cisplatin Combination Chemotherapy for Lung Cancer].

Yamashita K, Yoshino M, Sasaki N, Tanaka Y, Tanaka K, Abe M, Tagawa C, Kawahara F, Kato K, Kaise M, Tanaka H, Chou T. Yamashita K, et al. Among authors: tanaka k, tanaka h, tanaka y. Gan To Kagaku Ryoho. 2015 Nov;42(11):1379-83. Gan To Kagaku Ryoho. 2015. PMID: 26602395 Japanese.

7

Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.

Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, Hataji O, Takeda Y, Aoe K, Kim YH, Yokota S, Tabeta H, Tomii K, Ohashi Y, Eguchi K, Watanabe K. Takayama K, et al. Among authors: tanaka h. Support Care Cancer. 2016 Aug;24(8):3473-80. doi: 10.1007/s00520-016-3156-8. Epub 2016 Mar 22. Support Care Cancer. 2016. PMID: 27003901 Free PMC article.

8

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.

Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, Satouchi M, Hida T, Yoshimura N, Kozuki T, Imamura F, Kiura K, Okamoto H, Sawa T, Tamura T; JCOG0605 investigators. Goto K, et al. Among authors: tanaka h. Lancet Oncol. 2016 Aug;17(8):1147-1157. doi: 10.1016/S1470-2045(16)30104-8. Epub 2016 Jun 14. Lancet Oncol. 2016. PMID: 27312053 Clinical Trial.

9

Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).

Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K. Takahama T, et al. Among authors: tanaka h. Oncotarget. 2016 Sep 6;7(36):58492-58499. doi: 10.18632/oncotarget.11303. Oncotarget. 2016. PMID: 27542267 Free PMC article.

10

Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.

Kato T, Masuda N, Nakanishi Y, Takahashi M, Hida T, Sakai H, Atagi S, Fujita S, Tanaka H, Takeda K, Satouchi M, Namba Y, Tamura T. Kato T, et al. Among authors: tanaka h. Lung Cancer. 2017 Feb;104:111-118. doi: 10.1016/j.lungcan.2016.12.016. Epub 2016 Dec 21. Lung Cancer. 2017. PMID: 28212992 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,298 results

Search Page

Filters